BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Andravizou A, Dardiotis E, Artemiadis A, Sokratous M, Siokas V, Tsouris Z, Aloizou AM, Nikolaidis I, Bakirtzis C, Tsivgoulis G, Deretzi G, Grigoriadis N, Bogdanos DP, Hadjigeorgiou GM. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Auto Immun Highlights 2019;10:7. [PMID: 32257063 DOI: 10.1186/s13317-019-0117-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Gomez-Ramirez J, Quilis-Sancho J, Fernandez-Blazquez MA. A Comparative Analysis of MRI Automated Segmentation of Subcortical Brain Volumes in a Large Dataset of Elderly Subjects. Neuroinformatics 2021. [PMID: 33783668 DOI: 10.1007/s12021-021-09520-z] [Reference Citation Analysis]
2 Mamoei S, Jensen HB, Pedersen AK, Nygaard MKE, Eskildsen SF, Dalgas U, Stenager E. Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis-An Explorative Study. Front Neurol 2021;12:758710. [PMID: 34764932 DOI: 10.3389/fneur.2021.758710] [Reference Citation Analysis]
3 Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol 2020;11:1045. [PMID: 33071934 DOI: 10.3389/fneur.2020.01045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Lakin L, Davis BE, Binns CC, Currie KM, Rensel MR. Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review. Neurol Ther 2021;10:75-98. [PMID: 33877583 DOI: 10.1007/s40120-021-00239-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Bross M, Hackett M, Bernitsas E. Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis. Int J Mol Sci 2020;21:E4312. [PMID: 32560364 DOI: 10.3390/ijms21124312] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord 2021;55:103170. [PMID: 34364034 DOI: 10.1016/j.msard.2021.103170] [Reference Citation Analysis]
7 Orsi G, Hayden Z, Cseh T, Berki T, Illes Z. Osteopontin levels are associated with late-time lower regional brain volumes in multiple sclerosis. Sci Rep 2021;11:23604. [PMID: 34880402 DOI: 10.1038/s41598-021-03173-3] [Reference Citation Analysis]
8 Siokas V, Tsouris Z, Aloizou AM, Bakirtzis C, Liampas I, Koutsis G, Anagnostouli M, Bogdanos DP, Grigoriadis N, Hadjigeorgiou GM, Dardiotis E. Multiple Sclerosis: Shall We Target CD33? Genes (Basel) 2020;11:E1334. [PMID: 33198164 DOI: 10.3390/genes11111334] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Cox LM, Maghzi AH, Liu S, Tankou SK, Dhang FH, Willocq V, Song A, Wasén C, Tauhid S, Chu R, Anderson MC, De Jager PL, Polgar-Turcsanyi M, Healy BC, Glanz BI, Bakshi R, Chitnis T, Weiner HL. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol 2021;89:1195-211. [PMID: 33876477 DOI: 10.1002/ana.26084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
10 Rastogi A, Weissert R, Bhaskar SM. Brain atrophy in acute ischaemic stroke patients treated with reperfusion therapy: a systematic review. Acta Radiol 2021;:2841851211060427. [PMID: 34851161 DOI: 10.1177/02841851211060427] [Reference Citation Analysis]
11 Turalde CWR, Espiritu AI, Anlacan VMM. Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials. Front Neurol 2020;11:574748. [PMID: 33658967 DOI: 10.3389/fneur.2020.574748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Repovic P, Robertson D, Kresa-Reahl K, Cohan SL, Su R, Avila R, Koulinska I, Mendoza JP. Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND. Neurol Ther 2021;10:169-82. [PMID: 33225410 DOI: 10.1007/s40120-020-00223-2] [Reference Citation Analysis]
13 Bradshaw DV Jr, Knutsen AK, Korotcov A, Sullivan GM, Radomski KL, Dardzinski BJ, Zi X, McDaniel DP, Armstrong RC. Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures. Acta Neuropathol Commun 2021;9:89. [PMID: 34001261 DOI: 10.1186/s40478-021-01193-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Tanaka M, Vécsei L. Monitoring the Redox Status in Multiple Sclerosis. Biomedicines 2020;8:E406. [PMID: 33053739 DOI: 10.3390/biomedicines8100406] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
15 Kopchak OO, Odintsova TA. Cognitive impairment and depression in patients with relapsing-remitting multiple sclerosis depending on age and neuroimaging findings. Egypt J Neurol Psychiatr Neurosurg 2021;57:119. [PMID: 34511865 DOI: 10.1186/s41983-021-00376-3] [Reference Citation Analysis]